SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amid discussions around its potential within the broader crypto market, particularly in relation to new ETFs. Community members are actively debating price movements and future potential, with some anticipating a significant rise, while others express concerns about short-term volatility. The launch of a Hong Kong spot ETF has also spurred interest in the Asian market.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around the project, emphasizing its strong community and long-term vision. Some are pointing to the connection with Solana, while others highlight upcoming airdrops and staking opportunities as potential catalysts. Despite market volatility, holders express conviction in Brokecoin's potential.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending following strong earnings results, especially in its cloud services (AWS), fueling optimism and pushing the stock to new highs. The community is actively discussing potential price targets and whether this rally will hold, with some analysts forecasting further gains. Some are noting the company's layoffs despite strong earnings, while others point to the company's historically lagging performance as a reason for excitement.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as the community anticipates the impact of earnings and discusses the company's bitcoin holdings relative to its stock price. Bullish sentiment seems to be building with some traders betting on a run-up, while others remain skeptical of the company's long-term prospects and business model, especially with recent price action.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

$4CHAN is trending as community members discuss its potential as the 'Bitcoin of memecoins' and highlight its origin within meme culture. Amidst fluctuating prices, the community emphasizes holding, buying dips, and meme creation, while also referencing other memecoins like $PEPE, $SHIB and $HONK. Community members are speculating about future runs.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending amid news of increased competition and political pressure on drug pricing, sparking concerns about future profitability. The community is actively discussing the potential impact of these factors on NVO's market position, especially relative to competitors like Eli Lilly ($LLY).  Mergers and acquisitions may factor into the future of the company as it navigates the evolving landscape of the weight loss drug market.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending after reporting earnings, with initial reactions mixed as traders digest the details. Community discussions focus on iPhone sales and forward guidance, particularly CEO Tim Cook's optimistic outlook for the holiday quarter. Despite some concerns about China sales, the overall sentiment leans bullish, fueling speculation about the stock's potential to reach new highs.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending amid speculation of a potential sale, with SpaceX cited as a possible buyer, and the community is buzzing about the implications for Apple, a major partner. Discussions revolve around potential bidding wars and the true value of Globalstar's spectrum, with some suggesting a buyout could be significantly higher than current market capitalization. The potential sale could reshape the satellite communications landscape, especially given Globalstar's existing relationship with Apple.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid renewed speculation of a potential buyout, sparking heavy trading volume. The community is actively discussing possible acquirers, potential deal valuations, and the impact on current shareholders. Bullish sentiment also stems from pipeline progress outside of COVID vaccines, though some caution against over-optimism.

UP AND TO THE RIGHT

UPRIGHT CRYPTO is trending as community members highlight its strong foundation and potential for significant growth. Discussions revolve around chart analysis, disciplined trading, and the project's long-term vision. The community emphasizes patience and conviction, suggesting a belief in UPRIGHT's stability and consistent upward trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Biogen will obtain exclusive worldwide rights to Vanqua’s investigational drug that targets a protein involved in inflammatory responses.</li><li>Vanqua will receive $70 million upfront payments and will be eligible to receive up to $990 million in milestone payments.</li><li>Biogen will lead all future development, manufacturing, and commercialization efforts for the experimental drug.&nbsp; &nbsp;</li></ul>Biogen Inc. (BIIB) on Friday announced a license agreement with Vanqua Bio granting it exclusive worldwide rights to the latter’s preclinical drug candidate targeting a range of inflammatory disorders.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biogen.com/news-releases/news-release-details/biogen-licenses-oral-c5ar1-antagonist-vanqua-bio-expand">deal</a>, Biogen will obtain exclusive worldwide rights to Vanqua’s investigational drug that targets a protein involved in inflammatory responses.<h2 class="st-heading-2">Terms Of The Deal</h2>Vanqua will receive $70 million in upfront payments and be eligible to receive up to $990 million in milestone payments, in addition to tiered royalties on potential net sales, as per the agreement. Biogen will lead all future development, manufacturing, and commercialization efforts of the experimental drug.Jane Grogan, Executive Vice President and Head of Research at Biogen, said that advancing the program will enable it to deepen focus on immunological diseases.Biogen expects to file an application with the U.S. Food and Drug Administration for approval of the candidate in 2027, if results remain supportive. In preclinical studies, the program demonstrated activity as well as a safety and tolerability profile supportive of advancing it into clinical development, the company noted.Last year, Biogen also acquired privately held Human Immunology Biosciences for up to $1.8 billion to expand its immunology portfolio.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> rose 1% on Friday morning at the time of writing. On Stocktwits, retail sentiment around BIIB stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:620/59;" src="data:image/png;base64,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" width="620" height="59" alt="BIIB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>BIIB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>According to Koyfin data, 16 of the 35 analysts covering Biogen rate it ‘Buy’ or higher, while 19 rate it ‘Hold’. The stock has an average price target of $172.55, representing a potential upside of about 14%.BIIB stock is down by 1% this year and by about 18% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-acquire-adverum-biotechnologies/cLGJ8N0R3tc">Eli Lilly To Acquire Adverum Biotechnologies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal

Biogen will lead all future development, manufacturing, and commercialization efforts for the experimental drug. 

Equity

<ul class="summary-bullets"><li>The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion.&nbsp;</li><li>The company is banking on strong demand for its high-value product (HVP) components used in GLP-1 drugs for weight loss and diabetes management.&nbsp;</li><li>For Q3, West Pharmaceutical reported adjusted and diluted EPS of $1.92, compared to $1.85 in the same period last year.&nbsp; &nbsp;</li></ul>Shares of West Pharmaceutical Services (WST) soared 12% on Thursday afternoon after the company increased its full-year earnings guidance after its third-quarter earnings beat Wall Street expectations.The Pennsylvania-headquartered company, which manufactures packaging components and delivery systems for injectable drugs and healthcare products, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.westpharma.com/news-releases/news-release-details/west-reports-third-quarter-2025-results">raised</a> its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion.It also hiked its full-year adjusted earnings per share (EPS) outlook to $7.06 to $7.11, up from $6.65 to $6.85, citing strong demand for its high-value product (HVP) components used in GLP-1 drugs for weight loss and diabetes regulation. In Q3, HVP components accounted for 48% of the company's total net sales.The firm, however, flagged that it continues to anticipate $15 million to $20 million in tariff-related costs this year.<h2 class="st-heading-2">CEO Remarks</h2>Chief Executive Eric M. Green stated that several factors drove HVP component sales in Q3. “First, elastomers for GLP-1s had strong growth and now account for 9% of total company sales. We benefit from our longstanding relationships as we partner with our customers in this market, supporting them as they expand their GLP-1 franchises…We expect this market to continue to evolve as there are a number of new early-stage trials seeking to expand the range of indications and treatments using GLP-1s,” Green said.He added that the company, which includes weight-loss drugmakers Eli Lilly and Novo Nordisk among its customers, is also collaborating with customers who are launching new GLP-1 molecules and generics.<h2 class="st-heading-2">Third Quarter Earnings</h2>For the third quarter (Q3), West Pharmaceutical reported adjusted and diluted EPS of $1.96, compared to $1.85 in the same period last year, and above an analyst estimate of $1.68, according to data from Fiscal AI. Net sales increased 7.7% year-over-year to $804.6 million in the quarter.The company reported a 16.3% increase in net sales of its HVP components to $390 million in the quarter. Contract-manufactured products segment net sales, meanwhile, rose 8% to $157.1 million, driven by increased sales of self-injection devices for obesity and diabetes.Evercore ISI analyst Daniel Markowitz raised the firm's price target on West Pharmaceutical to $390 from $350 while keeping an ‘Outperform’ rating on the shares following the earnings call.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/WST">WST stock</a> improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:619/59;" src="data:image/png;base64,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" width="619" height="59" alt="WST's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Oct. 23, 2025 | Source: Stocktwits"><figcaption>WST's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Oct. 23, 2025 | Source: Stocktwits</figcaption></figure>WST stock is down by 5% this year but has risen over 8% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/staar-surgical-stock-rises-after-adjournment-of-stockholders-meeting-to-discuss-proposed-merger-with-alcon/cLG4FXDR3rj">STAAR Surgical Stock Rises After Adjournment Of Stockholders’ Meeting To Discuss Proposed Merger With Alcon</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a West Pharmaceutical Services logo is seen on a mobile phone screen in front of a graph. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

WST Stock Soars After Company Raises Full-Year Guidance On Strong Demand For GLP-1 Drug Components

The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion. 

Shares of Humana (HUM) rose 3% on Thursday afternoon after the company affirmed its full-year earnings per share guidance provided in July.The insurer stated that it expects adjusted earnings per common share of $17 for the year ending Dec. 31, 2025, and diluted earnings per share of $13.77.The firm also stated that its preliminary 2026 Medicare Advantage (MA) Star Ratings align with the assumptions in its financial planning. As a result, there is no change to the incremental earnings potential for 2025 to 2028. The ratings data provided by the Centers for Medicare and Medicaid Services was inadvertently accessible on CMS Plan Finder for a brief period on Oct. 1, 2025, the company stated.CMS assigns a star rating to Medicare Advantage plans, ranging from one to five, with five being the highest rating. Beneficiaries can use this data to help choose plans, and insurance companies can receive government bonus payments for higher ratings.Humana has about 20% of its members currently enrolled in Medicare plans rated four stars and above for 2026, and 14% of members in 4.5-star plans for 2026, it said.“Based on all information available to date, the company remains confident in its 2026 Individual MA pricing and benefit design, including the expectation that it will double individual MA pre-tax margin in 2026 (excluding Stars), and believes it is positioned to return to membership growth in 2026,” the firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/49071/000004907125000048/hum-20251002.htm">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HUM">HUM stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_1_48_22_PM_png_d2e549fd89.webp" alt="HUM's Sentiment Meter and Message Volume as of 2 p.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>HUM's Sentiment Meter and Message Volume as of 2 p.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user reported selling their holdings in Humana, citing excessive volatility.<stembedurl>https://stocktwits.com/Felo3179/message/630807403</stembedurl>HUM stock has risen 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immuron-stock-rallies-after-ceo-dismisses-us-pharma-tariff-impact/chCrSSWR3f5">Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The MyHumana app page is displayed on a smartphone in the Apple App Store in front of the Humana Inc logo on October 30, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Humana Stock Rises After Insurer Reaffirms Full-Year Earnings Guidance

The firm also stated that its preliminary 2026 Medicare Advantage Star Ratings align with the assumptions in its financial planning, and as a result, there is no change to the incremental earnings potential for 2025 to 2028.

Global X Funds - Global X S&P 500 Risk Managed Income ETF

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

XRMI
Global X S&P 500 Risk Managed Income

Feed

News

Sentiment

Fundamentals

Info

Latest XRMI News

XRMIGlobal X S&P 500 Risk Managed Income